Alkeus Secures $150M in Series B Financing for Groundbreaking Stargardt Disease Treatment

Cambridge, MA, June 5, 2023 (Globe Newswire) -- Alkeus Pharmaceuticals has sealed $150 million in Series B funding to cover the registration and commercialization of gildeuretinol (ALK-001), a potentially game-changing precision medicine for the treatment of Stargardt disease. This financing round, led by Bain Capital Life Sciences, will accelerate the development and approval process of gildeuretinol, addressing the underlying cause of Stargardt disease and offering hope to the thousands affected by this leading cause of blindness in children and young adults.

Read full article here.